Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
| Autor: | Joyce S. Lee, Venerino Poletti, Luca Richeldi, Susanne Stowasser, Martin Kolb, D Wachtlin, Christopher J. Ryerson |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Vital capacity lcsh:Medicine nintedanib idiopathic pulmonary fibrosis Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO Placebo Interstitial Lung Disease Gastroenterology 03 medical and health sciences Idiopathic pulmonary fibrosis chemistry.chemical_compound FEV1/FVC ratio 0302 clinical medicine Internal medicine Post-hoc analysis medicine In patient 030212 general & internal medicine Stage (cooking) business.industry lcsh:R Original Articles medicine.disease 3. Good health 030228 respiratory system chemistry Nintedanib business |
| Zdroj: | ERJ Open Research Ryerson, C J, Kolb, M, Richeldi, L, Lee, J, Wachtlin, D, Stowasser, S & Poletti, V 2019, ' Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage ', ERJ Open Research, vol. 5, no. 2, 00127-2018 . https://doi.org/10.1183/23120541.00127-2018 ERJ Open Research, Vol 5, Iss 2 (2019) |
| ISSN: | 2312-0541 |
| DOI: | 10.1183/23120541.00127-2018 |
| Popis: | We conducted a post hoc analysis to assess the potential impact of GAP (gender, age, physiology) stage on the treatment effect of nintedanib in patients with idiopathic pulmonary fibrosis. Outcomes were compared in patients at GAP stage I versus II/III at baseline in the INPULSIS® trials. At baseline, 500 patients were at GAP stage I (nintedanib 304, placebo 196), 489 were at GAP stage II (nintedanib 296, placebo 193) and 71 were at GAP stage III (nintedanib 38, placebo 33). In nintedanib-treated patients, the annual rate of decline in forced vital capacity (FVC) was similar in patients at GAP stage I and GAP stage II/III at baseline (−110.1 and −116.6 mL·year−1, respectively), and in both subgroups was lower than in placebo-treated patients (−218.5 and −227.6 mL·year−1, respectively) (treatment-by-time-by-subgroup interaction p=0.92). In the nintedanib group, the number of deaths was 43.8% of those predicted based on GAP stage (35 versus 79.9). In the placebo group, the number of deaths was 59.8% of those predicted based on GAP stage (33 versus 55.2). In conclusion, data from the INPULSIS® trials suggest that nintedanib has a similar beneficial effect on the rate of FVC decline in patients at GAP stage I versus II/III at baseline. Nintedanib provides a similar benefit versus placebo on the rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis irrespective of GAP stage at baseline http://ow.ly/HfJ730nNkRT |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|